VivoSeq
Other

High Risk Patients

0

Pipeline Programs↗

0

Active Trials↗

2

Companies Involved↗

High Risk Patients is an early-stage landscape with 0 programs across 2 companies. The most active players are SFJ Pharma Ltd. II, Boehringer Ingelheim.

Intelligence

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

69/100

Attrition Rate

29/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

S

SFJ Pharma Ltd. II

0 programs

PreclinicalBoehringer Ingelheim logo

Boehringer Ingelheim

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

14

clinical trials

Completed9 · 64%
Withdrawn2 · 14%
Terminated2 · 14%
Unknown status1 · 7%

Clinical Trials

Trial Activity

14 trials

A Study of COVID 19 Convalescent Plasma in High Risk Patients With COVID 19 Infection
Completed·TTriHealth Inc.·Phase 2·NCT04392232·159 enrolled
Fibrin Glue After ESD for High Risk Patients of Bleeding
Completed·SSeoul National University Hospital·N/A·NCT04602689·134 enrolled
Role of Hemostatic Powder (Endo-clotTM) in Prevention of Bleeding Within High Risk Patients After ESD
Completed·YYonsei University·Phase 3·NCT02625792·45 enrolled
ACRIPAB- Trial: Anti Coagulation Regimen In High Risk PAtients for Bleeding
Completed·HHaEmek Medical Center, Israel·Phase 3·NCT00616460·100 enrolled
Evaluation of the Effect of Telmisartan on Blood Pressure Control of High Risk Patients
Completed·Boehringer Ingelheim logoBoehringer Ingelheim·N/A·NCT01108809·295 enrolled
Peri-Operative And Long-Term Cardioprotective Properties Of Sevoflurane In High Risk Patients Undergoing Non-Cardiac Surgery
Completed·UUniversity Health Network, Toronto·Phase 4·NCT00336401
Levosimendan in High Risk Patients Undergoing Cardiac Surgery
Completed·UUniversità Vita-Salute San Raffaele·Phase 4·NCT00994825·1,000 enrolled
Non Invasive Cardiac Output Monitoring to Guide Goal Directed Fluid Therapy in High Risk Patients Undergoing Urgent Surgical Repair of Proximal Femoral Fractures
Completed·YYork Teaching Hospitals NHS Foundation Trust·N/A·NCT02382185·240 enrolled
Comparison of HD Chemotherapy Followed by Auto-transplant and R-CHOP in High Risk Patients With DLBCL.
Completed·GGruppo Italiano Terapie Innovative nei Linfomi·Phase 3·NCT00355199·246 enrolled
S-1/Oxaliplatin for High Risk Patients Who Underwent Gastrectomy
Terminated·KKangbuk Samsung Hospital·Phase 2·NCT02191566·8 enrolled
Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients
Terminated·SSFJ Pharma Ltd. II·Phase 3·NCT01599754·724 enrolled
Renal Effect of Pentoxyphylline in High Risk Patients Undergoing Angiography
Withdrawn·MMeir Medical Center·N/A·NCT01144091
Study of Fruquintinib (HMPL-013) in High Risk Patients With Advanced NSCLC
Withdrawn·HHutchison Medipharma Limited·Phase 2·NCT03684967
Clinical Trial Phase I/II Prospective, Open Nonrandomized for Treatmen of Postoperative Air Leak After Lung Resection in High Risk Patients Through the Administration of Mesenchymal Autologous Cells
Unknown status·RRed de Terapia Celular·Phase 1/2·NCT02045745·10 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)